| 摘要: |
| [摘要] 目的:探讨不同首剂量应用肺表面活性物质(PS) 对近足月新生儿呼吸窘迫综合征(NRDS) 的临床疗效及安全性。 方法:选择我院2011 年 7 月至 2016 年 7 月收治的近足月 NRDS 患儿共 90 例,以随机区组法分为 A、B、C 三组各 30 例,分别给予
PS 首剂量 40、70、90 mg/kg 辅助治疗,比较三组患儿的机械通气时间、供氧时间、住院时间、PS 重复给药次数及治疗前后 PaO2、 PaCO2、OI 和肺部 X 线片评分、院内肺炎发生率。 结果:三组患儿机械通气时间、供氧时间、住院时间、PS 重复给药次数、院内肺 炎发生率及治疗后的
PaCO2、OI 和肺部 X 线片评分排序为 C 组0.05)。 结论:PS 首剂量 90 mg/kg 应用于近足月
NRDS,可有效缩短机械通气时间和住院时间,减少 PS 重复给药次数,提高肺部通气功能,有助于避免院内肺炎 发生风险,临床价值优于
40 mg//kg 和 70 mg/kg。 |
| 关键词: 肺表面活性物质 近足月早产儿 新生儿呼吸窘迫综合征 首剂量 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2018.03.005 |
|
| 基金项目: |
|
| Influence of Different Primary Dose of Pulmonary Surfactant on Near-Term Infants with NeonatalRespiratory Distress Syndrome |
| Wang Yanqing |
| (Yangzhou Maternal and Child Health Care Hospital, Jiangsu Yangzhou 225000, China) |
| Abstract: |
| [Abstract] Objective: To investigate the influence of different primary dose of pulmonary surfactant (PS) on near-term infants with
neonatal respiratory distress syndrome (NRDS). Methods: Ninety near-term infants with NRDS were chosen in our hospital from July
2011 to July 2016, they were randomly divided into 3 groups including group A (30 children) with primary dose of PS for 40 mg / kg,
group B (30 children) with primary dose of PS for 70 mg/kg and group C (30 children) with primary dose of PS for 90 mg/kg. The
mechanical ventilation time, oxygen used time, hospitalization time, PS administration times, the levels of PaO2, PaCO2, OI before and
after treatment, pulmonary X-ray score, pneumonia incidence of 3 groups were compared. Results: The mechanical ventilation time,
oxygen used time, hospitalization time of group C were significantly shorter than group A and group B (P<0.05), and the group B were
significantly shorter than group A (P<0.05). The PS administration times and pneumonia incidence of group C were significantly fewerthan group A and group B (P<0.05), and the group B were significantly fewer than group A (P<0.05). The levels of PaO2, PaCO2, OI after treatment, and pulmonary X-ray score of group C were significantly better than group A and group B, 3 groups were significantly better than before treatment ( P<0.05). There was no significant difference in the PaO2 level after treatment among 3 groups ( P>0.05). Conclusion: Compared with primary dose of PS for 40 mg/kg and 70 mg/kg, primary dose of PS for 90 mg/kg in the treatment of near-term infants with NRDS can efficient shorten the ventilation time and hospital staying time, reduce the dosage of PS once again, the pulmonary ventilation function and be helpful to avoid the risk of pneumonia. |
| Key words: pulmonary surfactant near-term infants neonatal respiratory distress syndrome primary dose |
